Contribute Try STAT+ Today

A little more than one year ago, I wrote a skeptical article about Endocyte (ECYT), a small, down-on-its-luck biotech that had just licensed an experimental prostate cancer drug in what the CEO called a “transformational” transaction.

Endocyte shares popped from $1 to $4 on the September 2017 deal, which I called out as an over-hyped reaction to some overly promotional claims made by the company and CEO Mike Sherman. The excitement over that “transformational” prostate cancer drug was more likely to end in disappointment, I wrote.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Don’t beat yourself up too much, history is littered with big pharmas’ bad investments. And Novartis bought Ablinx as well, so … there still time to watch their bodies floating down the river

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy